Molbio Diagnostics Targets ₹940 Crore in IPO for Expansion and Stake Reduction

Molbio Diagnostics, a leading name in molecular diagnostics, has announced plans to launch an initial public offering (IPO) aiming to raise ₹940 crore. The company intends to allocate ₹200 crore from this fresh issuance towards capital expenditures, while an additional ₹740 crore will be generated through an offer for sale, reducing the promoter group's stake from 46.6% to 43%.

Expanding Global Reach and Capabilities

Founded in 2000, Molbio operates six manufacturing facilities across India and serves clients in over 90 countries. Its clientele includes government health programs, diagnostic laboratories, hospitals, and international health organizations. The company's flagship product, the 'Truenat' platform, is a portable diagnostic system designed for resource-constrained settings, offering rapid and accurate testing for over 30 diseases. This innovation has been especially impactful in tuberculosis diagnostics, with these test kits accounting for 70% of the company's kit sales.

Molbio's growth strategy is closely tied to its ability to cater to large-scale health initiatives, with government and international aid agencies making up over 80% of its revenue. The firm's top customers contribute more than half of its total revenue, highlighting a significant customer concentration risk.

Financial Performance and Market Position

Between FY24 and FY26, Molbio reported a 31.5% annual increase in revenue from operations, reaching ₹1,445.7 crore. The net profit saw a 40.2% annual rise, amounting to ₹164.1 crore. The company's EBITDA grew by 33.2% to ₹328.2 crore, with the margin improving slightly to 22.6% in FY26 from 22% in FY24. On a year-over-year basis, FY26 witnessed a 41.7% surge in revenue, a 27.9% rise in EBITDA, and an 18.4% increase in net profit.

Despite the absence of directly comparable listed peers in India, Molbio’s valuation is competitive with existing healthcare diagnostics firms like Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre, which trade at P/E multiples ranging from 54 to 81. Post-IPO, Molbio is expected to demand a price-earnings multiple of up to 57.

Investment Considerations

For investors with a high-risk tolerance, Molbio Diagnostics' IPO presents an intriguing opportunity for long-term growth. The company's established global presence, innovative product offerings, and robust financial performance provide a solid foundation for future expansion. However, the heavy reliance on a concentrated customer base and the competitive valuation should be carefully weighed.